Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
59.71(c) 54.21(c) 53.25(c) 53.175(c) 52.47(c) Last
1 846 964 1 663 840 1 138 811 845 099 936 232 Volume
+8.07% -9.21% -1.77% -0.14% -1.33% Change
More quotes
Financials ($)
Sales 2017 76,0 M
EBIT 2017 -457 M
Net income 2017 -456 M
Finance 2017 356 M
Yield 2017 -
Sales 2018 162 M
EBIT 2018 -417 M
Net income 2018 -410 M
Finance 2018 227 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 54,8x
EV / Sales2018 26,5x
Capitalization 4 515 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
03/17 THE MEDICINES COMPANY : and Alnylam Pharmaceuticals Report Positive Final Result..
03/16 ALNYLAM PHARMACEUTICALS : Reports Outline Internet, Networks and Communications ..
03/09 ALNYLAM PHARMACEUTICALS : Reports from Alnylam Pharmaceuticals, Inc. Highlight R..
03/09 ALNYLAM PHARMACEUTICALS : Receives European Medicines Agency PRIME Designation f..
03/03 ALNYLAM PHARMACEUTICALS : Receives European Medicines Agency PRIME Designation f..
03/01 ALNYLAM PHARMACEUTICALS : Receives European Medicines Agency PRIME Designation f..
02/28 ALNYLAM PHARMACEUTICALS : Acknowledges Rare Disease Day by Highlighting Services..
02/27 ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming March Investor Co..
02/16 ALNYLAM PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2016 Financial Re..
02/16 ALNYLAM PHARMACEUTICALS : Presents New Data on Fitusiran at EAHAD
More news
Sector news : Biotechnology & Medical Research - NEC
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
03/24 Amgen reported positive data for , what future for Alnylam and TMC's PCSK9 i..
4
03/21After a rough year in the trenches, Alnylam CEO John Maraganore and his team ..
1
03/20Alnylam Pharmaceuticals's buy rating reiterated at FBR & Co.
1
03/20$ALXN license deal may open gate for more with LNP, says Arbutus CEO. $ALNY a..
2
03/20In light of Fourier data, what future for Alnylam and TMC's PCSK9 inclisiran?..
5
More tweets
Qtime:22
News from SeekingAlpha
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/17 AMGEN TANKS ON REPATHA DATA : Analysis
03/17 Amgen -6%, MDCO -22%, ESPR -30% after Repatha data
03/13 Omeros Corporation's Q4 Sales Matter
03/07 Repatha's Next Challenge Is Expectations
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 66,4 $
Spread / Average Target 27%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Michael P. Mason Treasurer & Principal Accounting Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICAL..40.14%4 515
INCYTE CORPORATION39.26%28 461
QUINTILES IMS HOLDINGS..2.55%18 400
LONZA GROUP AG3.40%10 646
CELLTRION, INC.--.--%9 851
SEATTLE GENETICS, INC.20.69%9 075
More Results